Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

AbCellera scientists examine cell cultures on a microscope as part of a cell biology assay. The Vancouver company received a US$15-million milestone payment from Eli Lilly, plus US$198.3-million in royalties in 2020.

Courtesy of manufacturer

AbCellera Biologics Inc.’s efforts to quickly identify a COVID-19 treatment has paid off for the Vancouver company.

AbCellera, which became Canada’s most valuable biotechnology company after its record-setting initial public offering in December, said Monday it generated US$233-million in revenue and a net profit of US$119-million for 2020. That was up from US$11.6-million revenue and a US$2-million loss in 2019. Almost all of that bounty was because of its partnership with Eli Lilly & Co., inked last May, which saw the drug giant take to market an antibody-based treatment for COVID-19 patients, called bamlanivimab.

AbCellera received a US$15-million milestone payment from Eli Lilly , plus US$198.3-million in royalties in 2020. More than 85 per cent of the year’s revenue came in the fourth quarter.

Story continues below advertisement

The bounty is set to continue. Chief financial officer Andrew Booth said during a conference call with analysts that AbCellera expects first quarter revenue of US$190-million to US$210-million, mostly from royalties.

Its treatment has been approved for use in 15 countries, including the United States and Canada, and given to more than 400,000 patients – typically those recently diagnosed with mild or medium COVID-19 symptoms. It is now being administered in combination with another antibody to increase its effectiveness. AbCellera says use of its treatment has reduced hospitalization by 70 per cent to 80 per cent in recently diagnosed patients and cut the risk of contraction in nursing homes by up to 80 per cent.

Meanwhile, AbCellera has developed another antibody with Eli Lilly shown to be effective in preclinical studies against all circulating variants of COVID-19. It is expected to be in clinical trials in the next three months and approved for emergency use by midyear. Chief executive Carl Hansen said AbCellera has shown it can “respond in real time with solutions that evolve along with the pandemic.” He expects COVID-19 will peak this year “but that it does not go to zero” and that the virus will be an endemic problem providing demand for AbCellera’s antibodies “for years to come.”

The earnings report was AbCellera’s first as a public company after a breakthrough 2020. The company isolated its antibody from the blood sample of a recovered COVID-19 patient after less than 90 days last spring, using its “antibody discovery engine” technology. The platform runs blood samples from a person who has developed immunity to a disease through a credit-card-sized device with hundreds of thousands of tiny chambers. With the help of artificial intelligence, it tests antibodies produced by cells in each chamber simultaneously to determine which have potential to become drugs – a faster, cheaper process for drug discovery than conventional methods.

The B.C. company, which spun out of the University of British Columbia’s Interdisciplinary Michael Smith Laboratories in 2012, has entered into more than 100 partnerships with 27 different partners to find antibody treatments for a range of ailments. Each deal provides AbCellera with research fees, milestone payments and royalties as molecules advance from the lab to market.

But AbCellera has met with disappointment at home with its first blockbuster drug. Despite Health Canada ordering 26,000 doses of the treatment, it has been almost untouched in Canada, as no province has recommended its use as a standard of care. In an editorial for the Daily Hive website in March, Dr. Hansen expressed frustration that provincial inaction on bamlanivimab “runs contrary to the recommendations made by the world’s foremost regulatory bodies … so many more Canadian patients could and can benefit from antibody therapy if only they could access it.”

AbCellera had US$594-million in cash and equivalents at year-end. It completed a venture capital financing last year and secured US$126-million in aid from the federal government to help build a manufacturing facility. Its December IPO on Nasdaq generated US$556-million in gross proceeds. The company, which has more than 200 employees, plans to expand its facilities and hire hundreds of people.

Story continues below advertisement

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies